Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03195205 | Identification to Elimination in HCV-Infected Individuals | EARLY_PHASE1 | COMPLETED | 3,051 | — | — | Jun 1, 2017 | Apr 20, 2020 | Jul 2, 2020 | 1 | United States |
The study will measure the percentage of patients screened for Hepatitis C who are reactive by detecting HCV antibodies.
| Arm | Type | Description |
|---|---|---|
| High-Risk Patients | OTHER | OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations |
| Name | Type | Description |
|---|---|---|
| OraQuick HCV Rapid Antibody Test | DIAGNOSTIC_TEST | HCV Screening |
Inclusion Criteria: Subjects will be included in the study if the following criteria is met: 1. The subject must be an Opioid Substitution Treatment patient. 2. The subject must fall into another high-risk population for the HCV. Exclusion Criteria: Subjects may be excluded from the study if the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |